Evidence map›Paper›PMID 16303100›Full record

ReviewCurrent rheumatology reports2005

Autoimmune mechanisms in children with systemic lupus erythematosus.

Dorothee Stichweh, Virginia Pascual

Abstract readComparative StudyReview
PubMed Publisher
In one paragraph

Review in Current rheumatology reports, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Dorothee StichwehBaylor Institute for Immunology Research, Dallas, TX 75204, USA.
Virginia Pascual
Baylor Institute for Rehabilitation · USBaylor University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the pathogenesis of SLE remains poorly understood, there is consensus that it involves a combination of genetic, hormonal, and environmental factors. New technologies applied to genomic and gene expression studies have revealed novel gene mutations and cytokine alterations in this disease. Recently, advances in monoclonal antibodies and recombinant DNA technology have resulted in the development of new drugs to arrest disease progression and restore physiologic immune responses without major side effects. Clinical trials to test several of these novel therapies are currently underway.

Indexed as

Age FactorsAntibodies, MonoclonalApoptosis Regulatory ProteinsAutoimmune DiseasesAutoimmunityChildChild, PreschoolCombined Modality TherapyDisease ProgressionFemaleHematopoietic Stem Cell TransplantationHumansImmunosuppressive AgentsLupus Erythematosus, SystemicMalePrognosisAntibodies, MonoclonalApoptosis Regulatory ProteinsImmunosuppressive Agents

Identifiers

PMID16303100
OpenAlexW2013380133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.